Reduction of Tumor Lysis Syndrome Risk after Debulking with Obinutuzumab in Patients Treated with Venetoclax-Obinutuzumab in the Randomized Phase 3 CRISTALLO TrialPaolo Sportoletti, Jeff P. Sharman, Emmanuelle Ferrant et al.|Blood|2024Cited by 0